DEA warns that ADHD over prescription could be as bad as OPIOID CRISIS
DEA warns that ADHD over prescription could be as bad as OPIOID CRISIS in stinging letter to pharmaceutical giants it accuses of 'aggressive marketing' | The Drug Enforcement Administration (DEA) has expressed concern that 'aggressive marketing practices' by telehealth companies may be contributing to excessive prescriptions for medications used to treat attention deficit hyperactivity disorder (ADHD), according to a letter from the agency. ● While the letter does not mention specific companies, it is believed to refer to telehealth companies such as Cerebral Inc. and Done Global Inc., whose prescribing practices have reportedly been under investigation by the DEA after blitzing social media with online adverts including Instagram and Facebook. ● This decision follows a more than doubling in Adderall prescriptions of more than 10% per year in 2021 through to October 2022, after a roughly 5% annual increase in the three years prior, according to data from research firm IQVIA. ● Adderall and the amphetamines used to make it are classified as Schedule II controlled substances by the DEA due to their high potential for abuse, along with opioids such as OxyContin and fentanyl. ● The DEA is legally required to set production quotas each year for ingredients in Schedule II drugs. ● In December, the DEA announced that it would not permit any increase in the production of pharmaceutical ingredients used to make Adderall and other stimulants for ADHD treatment in 2023.
No feedback yet
